01 / 18
Clinical Education Series

Postpartum Addiction Psychiatry

Maintaining Recovery Through the Highest-Risk Window

For PMHNPs, Addiction Fellows, and OB-GYN Collaborators
Disclosure: This presentation discusses off-label medication use in the perinatal period based on available evidence and clinical guidelines. Practice may need to be adapted to institutional protocols and state-specific regulations.
02 / 18
Session Framework

Learning Objectives

👤

Patient Care

  • Apply MOUD management principles across the perinatal continuum
  • Counsel patients on breastfeeding-medication compatibility
🧠

Medical Knowledge

  • Recognize NAS pathophysiology and evidence-based management
  • Identify PPD-SUD comorbidity and treatment priorities
⚖️

Systems-Based Practice

  • Navigate mandatory reporting requirements and CPS involvement
  • Implement warm handoff protocols across care transitions
🎯

Key Takeaway

  • The 7-12 month postpartum window is the highest-risk period
  • Continuity of care is the single most important intervention
03 / 18
Epidemiological Context

Why This Matters

7–12 Months
Peak overdose risk period. The patient stable in your prenatal clinic is at greatest risk months later.
04 / 18
Foundational Concepts

Five Core Principles

1️⃣

MOUD Should Continue

Discontinuation after delivery is the highest risk factor for relapse and overdose death

2️⃣

Breastfeeding is Compatible

Both buprenorphine and methadone are compatible with breastfeeding — benefits outweigh minimal transfer

3️⃣

PPD and SUD are Synergistic

Untreated depression drives relapse; active use worsens depression — treat both

4️⃣

NAS is Expected, Not a Failure

NAS is NOT a reason to withhold MOUD — undertreating harms both mother and infant

💡 Remember: Child welfare involvement requires trauma-informed navigation — punitive approaches drive patients underground
05 / 18
Interactive Case

Case 1 — Maria

Clinical Scenario
  • 28-year-old G2P2, delivered at 38 weeks
  • On buprenorphine 16mg daily throughout pregnancy
  • No other substance use, engaged in prenatal care
  • Infant now 36 hours old, showing early NAS signs
  • Patient asks: "Should I stop my medication so the baby doesn't suffer?"
What is your response?▸
Key Teaching:

NAS is evidence of treatment, not failure. Without maternal MOUD, we might not be having this conversation. Frame it positively: "Your baby is showing signs because you were in treatment — that's what kept both of you alive."

Never taper or discontinue maternal MOUD to reduce NAS — it doesn't work and increases overdose risk.

06 / 18
Medication Comparison

MOUD Comparison

Parameter Buprenorphine Methadone
NAS Incidence ~50% (shorter duration) ~70% (longer duration)
NAS Severity vs. Dose NO CORRELATION — Do NOT taper to reduce NAS
Breastfeeding ✓ Compatible (<2% RID) ✓ Compatible (low transfer)
Postpartum Product Can resume combo (naloxone) Continue same formulation
Dosing Postpartum May need increase (metabolic changes) May need increase postpartum
Monitoring PDMP checks, UDS per protocol — unchanged
💡 Clinical Pearl: Both medications work. Choice is shared decision-making, not one-size-fits-all. MOTHER trial showed both are safe (Jones et al., NEJM 2010).
07 / 18
Medication Safety

Breastfeeding Compatibility

Medication Compatible? Notes
Buprenorphine ✓ YES Relative infant dose <2% — encouraged
Methadone ✓ YES Low transfer; may reduce NAS severity
Naltrexone Likely safe Limited data; discuss risks/benefits
Sertraline (SSRI) ✓ YES First-line for PPD — best breastfeeding data
Benzodiazepines Caution Sedation risk; short-acting preferred if needed
Gabapentin Caution Moderate transfer; monitor infant sedation
Stimulants ✗ NO Significant transfer; infant cardiovascular risk
⚠️ Critical Pitfalls:
  • Do NOT stop MOUD to facilitate breastfeeding — overdose risk exceeds any medication risk
  • Active illicit use is the contraindication, not MOUD
  • HIV-positive patients should not breastfeed regardless of MOUD status
08 / 18
Comorbidity Management

Postpartum Depression & SUD

40–60%
of women with perinatal SUD have comorbid depression or anxiety

📋 Screening Protocol

  • EPDS at 2 weeks, 6 weeks, 3 months, 6 months
  • PHQ-9 as adjunct
  • GAD-7 for anxiety (often drives relapse)
  • PCL-5 for trauma/PTSD

💊 Treatment Hierarchy

  • 1st line: SSRI + psychotherapy (IPT/CBT)
  • 2nd line: SNRI if SSRI inadequate
  • Adjunct: Peer support, recovery housing
  • Avoid: Benzodiazepines when possible
🎯 Key Insight: Untreated PPD is the strongest predictor of postpartum relapse. Treat depression aggressively.
09 / 18
Neonatal Outcomes

Neonatal Abstinence Syndrome

💡 Key Insight:

NAS is a predictable, treatable, time-limited condition. It is NOT a complication of good treatment — it is an expected consequence of appropriate MOUD that keeps the mother alive and in recovery.

📊 Epidemiology

  • Occurs in 40–80% of opioid-exposed neonates
  • Severity does NOT correlate with maternal dose
  • Most resolve with supportive care alone

🏥 Management

  • 20–40% require pharmacologic treatment
  • Morphine taper is standard
  • Breastfeeding significantly reduces severity/duration
⚠️ Do NOT make the mother feel guilty about NAS — it is evidence that she was in treatment. Frame prenatally for better outcomes.
10 / 18
Clinical Algorithm

NAS Management Algorithm

1
Rooming-in
Keep infant with mother
→
2
Skin-to-skin
Kangaroo care
→
3
Swaddling
Low stimulation
→
Finnegan ≥8 ×3 or ≥12 ×1?
→
✓
Morphine
Taper as tolerated
🎯 ESC Model: Eat, Sleep, Console — non-pharmacologic interventions reduce pharmacologic treatment by ~50%. Breastfeeding is part of this.

📈 Finnegan Scoring

Threshold: Score ≥8 on three consecutive assessments OR ≥12 once

⏱️ Expected Course

Onset 24–72 hours; peak 2–5 days; resolution 5–7 days (up to 4 weeks if treated)

11 / 18
Legal/Ethical Challenge

Case 2 — CPS Involvement

Mandatory Reporting Scenario
  • 32-year-old on methadone 80mg, delivered at term
  • Urine toxicology: cannabis positive (no other substances)
  • Infant with mild NAS, responding to supportive care
  • Nurse states: "I have to call CPS on this positive drug screen"
  • Patient is engaged, attending all visits, on stable dose
How do you respond?▸
Key Teaching:

A positive toxicology alone is not child abuse. Many states have safe harbor provisions for patients in MOUD treatment. Your role: document, advocate, frame the narrative around recovery.

Proactive CPS navigation > reactive damage control. Offer to coordinate with caseworkers. Treatment engagement is protective.

12 / 18
Legal Framework

Navigating Mandatory Reporting

⚠️ Mandatory reporting varies by state Know your jurisdiction's requirements for substance-exposed newborns
⚠️ Safe harbor provisions exist Many states protect patients engaged in treatment — A positive screen alone is not abuse
⚠️ Punitive policies increase mortality States with criminal prosecution have higher maternal and infant death rates
⚠️ Coerced testing violates autonomy Informed consent for drug testing must be explicit
⚠️ Document everything Treatment attendance, toxicology trends, engagement milestones — this protects both patient and provider
💡 Protective Documentation: The same documentation that protects your patient protects you. Frame everything around recovery and treatment engagement.
13 / 18
Risk Stratification

The 7–12 Month Window

0
Delivery
1
1 Month
3
3 Months
⚠️
7–12 Months
12+
1 Year+
🚨 The Perfect Storm:
  • Loss of OB follow-up & prenatal program discharge
  • Insurance coverage gaps
  • Return of fertility & relationship stress
  • Accumulated sleep deprivation
  • Partner substance use (strongest environmental trigger)
14 / 18
Clinical Wisdom

Practical Pearls

🎯 Partner Use Screening:>/strong> Screen partners for substance use as carefully as you screen patients. It's equally important.
15 / 18
Systems-Based Practice

Warm Handoff Protocol

1
Prenatal
Identify high-risk
Plan for transition
→
2
Delivery
OB notifies psych
Social work engaged
→
3
0–6 Weeks
Psych outreach
Telehealth bridge
→
4
2–12 Months
Monthly psychiatry
High monitoring
→
5
Ongoing
Continue MOUD
Treat PPD/SUD
⚠️ The Gap: Patients lost in transition are the ones who die. Identify them. Call them. Keep them.
16 / 18
Knowledge Check

Test Yourself

A 26-year-old on methadone 100mg daily delivers at term. Her mother asks if she should taper the methadone to reduce the baby's NAS. What is the correct response?
A Yes, taper to 40mg over 2 weeks to reduce NAS severity
B No — NAS severity does NOT correlate with dose; maternal stabilization is the priority
C Switch to buprenorphine immediately postpartum to reduce NAS
D Taper by 10mg weekly while monitoring for withdrawal
Correct! NAS severity does NOT correlate with maternal MOUD dose. Tapering maternal medication to reduce NAS is a common board trap. The maternal overdose risk from discontinuation far exceeds any NAS concern.
17 / 18
Summary

Bottom Line

1. Continue MOUD

Through delivery and beyond. Discontinuation is the highest risk factor for relapse and overdose.

2. Treat Depression

Aggressively. Untreated PPD is the strongest predictor of postpartum relapse.

3. Support Breastfeeding

Both buprenorphine and methadone are compatible. Benefits outweigh minimal transfer.

4. Frame NAS Positively

It's expected, manageable, and evidence of treatment engagement — not failure.

5. Navigate CPS Proactively

Document treatment engagement. Frame narrative around recovery.

6. Watch the 7–12 Month Window

Highest overdose risk. Warm handoffs between prenatal and postpartum care save lives.

18 / 18
Resources

References & Resources

ACOG Committee Opinion 711: Opioid Use and Opioid Use Disorder in Pregnancy (reaffirmed 2024)
SAMHSA Clinical Guidance (2023): Treating Pregnant and Parenting Women with Opioid Use Disorder
Jones HE et al. (2010): Neonatal abstinence syndrome after methadone or buprenorphine exposure. N Engl J Med. MOTHER trial — Landmark study
Krans EE et al. (2023): Postpartum opioid-associated overdose deaths. Obstet Gynecol.
ABM Clinical Protocol #21 (2022): Breastfeeding and Substance Use
Hudak ML et al. (2012): Neonatal Drug Withdrawal. AAP Committee on Drugs
Patient Resources: MotherToBaby (mothertobaby.org) — evidence-based information on medications in pregnancy and lactation
📧 Questions? Contact: [Presenter contact] | Resources: Interactive HTML version available in shared folder